# Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies

> **NCT07110194** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.** · enrollment: 75 (estimated)

## Conditions studied

- CD20-positive Hematological Malignancies

## Interventions

- **DRUG:** TQB2825 Injection (Subcutaneous Injection)

## Key facts

- **NCT ID:** NCT07110194
- **Lead sponsor:** Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2026-03
- **Final completion:** 2027-12
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07110194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07110194, "Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07110194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*